Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Meletios Α. Dimopoulos(Korea University), Jesús F. San Miguel(Clinica Universidad de Navarra), Nelson Leung(WinnMed), Patrizia Tosi(Azienda Unità Sanitaria Locale Della Romagna), Brian G.M. Durie(Cedars-Sinai Medical Center), Sundar Jagannath(Mount Sinai Hospital), Heinz Ludwig(Wilhelminen Hospital), Joan Bladé(Hospital Clínic de Barcelona), Kenneth C. Anderson(Dana-Farber Cancer Institute), Raymond L. Comenzo(Tufts Medical Center), Evangelos Terpos(National and Kapodistrian University of Athens), Paul G. Richardson(Harvard University), Orhan Sezer(Charité - Universitätsmedizin Berlin), Antonio Palumbo(University Hospital Brno), S. Vincent Rajkumar(WinnMed), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Michèle Cavo(Unknown), Rubén Niesvizky(Cornell University), Jean‐Luc Harousseau(Hospital de Santa Maria), Asher Chanan-Khan(Memorial Sloan Kettering Cancer Center), Bart Barlogie(University of Arkansas for Medical Sciences), Jean-Paul Fermand(Hôpital Saint-Louis), Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 409
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k